Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance
J Wu, Z Lin - International journal of molecular sciences, 2022 - mdpi.com
The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …
Osimertinib resistance: molecular mechanisms and emerging treatment options
Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer
PURPOSE The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor)
has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAF …
has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAF …
Nanomedicine combats drug resistance in lung cancer
Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …
Real-world experience in treatment of patients with non-small-cell lung cancer with Braf or Cmet exon 14 skipping mutations
U Janzic, W Shalata, K Szymczak… - International Journal of …, 2023 - mdpi.com
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in
these cases for the first and second line is not clear. An international registry was created for …
these cases for the first and second line is not clear. An international registry was created for …
Pathways and targeting avenues of BRAF in non-small cell lung cancer
EN Imyanitov, NV Mitiushkina, ES Kuligina… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction BRAF is a serine-threonine kinase implicated in the regulation of MAPK
signaling cascade. BRAF mutation-driven activation occurs in approximately 2–4% of …
signaling cascade. BRAF mutation-driven activation occurs in approximately 2–4% of …
Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
Immune checkpoint inhibitors (ICIs) redefined the therapeutics of non-small cell lung cancer
(NSCLC), leading to significant survival benefits and unprecedented durable responses …
(NSCLC), leading to significant survival benefits and unprecedented durable responses …
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer
L Mezquita, M Oulhen, A Aberlenc, M Deloger… - British Journal of …, 2024 - nature.com
Background Resistance mechanisms to combination therapy with dabrafenib plus trametinib
remain poorly understood in patients with BRAF V600E-mutant advanced non-small-cell …
remain poorly understood in patients with BRAF V600E-mutant advanced non-small-cell …
Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings
D Haynes, EE Morgan, EY Chu - Human Pathology, 2023 - Elsevier
Targeted cancer treatments—designed to interfere with specific molecular signals
responsible for tumor survival and progression—have shown benefit over conventional …
responsible for tumor survival and progression—have shown benefit over conventional …
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Simple Summary Cancer is a heterogeneous disease characterized by uncontrollable
abnormal cell growth. KRAS plays a crucial role in cell proliferation and differentiation …
abnormal cell growth. KRAS plays a crucial role in cell proliferation and differentiation …